Morgan Stanley Starts Elan (ELN) at Overweight
More News related to BIIB
- Low Investor Sentiment Provides Buying Opportunity in Biogen (BIIB) -BWS Financial
- Biogen Idec to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference
- Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
- Notable Analyst Rating Changes 11/03: WMT, BIIB, NVDA, SLB Upgraded; SSCC, DO, HAL, PHM Downgraded
- Morning Movers 11/03: VeraSun (VSE) Sinks On Bankrupcty; Goodyear (GT) and Oshkosh (OSK) Up On Results
More News related to ELN
- Holzer Holzer & Fistel, LLC Announces That It Has Filed a Shareholder Class Action Against Elan Corporation, plc (NYSE: ELN)
- Mary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
- Elan (ELN) Announces Carlos V. Paya, MD, PhD, Will Become Company President
- Carlos V. Paya, MD, PhD, to Join Elan as Company President
- Scott+Scott LLP Files Class Action Lawsuit Against Elan Corporation, plc On Behalf of Investors -- ELN
More News related to New Coverage
- B. Riley Downgrades Doral Financial (DRL) to Neutral
- CL King Downgrades Ceragon (CRNT) to Accumulate
- Matrix Upgrades/Downgrades for December 1, 2008
- Raymond James Downgrades Allscripts (MDRX) to Market Perform
- RBC Capital Downgrades Strategic Hotels & Resorts (BEE) to Underperform
Morgan Stanley initiates coverage on Elan (NYSE: ELN) with an Overweight rating, citing valuation and its view that Tysabri's withdrawal is a low probability event.
In July, Elan and partner Biogen Idec (Nasdaq: BIIB) notified relevant regulatory agencies of two confirmed cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with TYSABRI in the commercial setting.
Related Categories
New CoverageStocks Mentioned
-3.29
+0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
